What Neuspera’s 12-month iSNM trial data means for the sacral neuromodulation competitive landscape
Neuspera Medical’s 12-month pivotal SNM trial shows 94% responder rates and zero infections. Analysing what this means for the SNM market. Read more.
Can Francis Medical’s Vanquish system reshape minimally invasive prostate cancer treatment?
Francis Medical launches commercial Vanquish procedures for prostate tissue ablation. Explore what this means for minimally invasive prostate cancer treatment.
What makes Break Wave different? SonoMotion’s FDA clearance puts ultrasound lithotripsy in the spotlight
SonoMotion’s Break Wave lithotripsy device wins FDA clearance for non-invasive kidney stone treatment. Find out what this changes for urology practices.